<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">EFORT Open Rev</journal-id><journal-id journal-id-type="iso-abbrev">EFORT Open Rev</journal-id><journal-id journal-id-type="pmc-domain-id">3182</journal-id><journal-id journal-id-type="pmc-domain">efortor</journal-id><journal-id journal-id-type="publisher-id">eor</journal-id><journal-title-group><journal-title>EFORT Open Reviews</journal-title></journal-title-group><issn pub-type="epub">2058-5241</issn><publisher><publisher-name>Bioscientifica Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10155122</article-id><article-id pub-id-type="pmcid-ver">PMC10155122.1</article-id><article-id pub-id-type="pmcaid">10155122</article-id><article-id pub-id-type="pmcaiid">10155122</article-id><article-id pub-id-type="pmid">37097051</article-id><article-id pub-id-type="doi">10.1530/EOR-22-0117</article-id><article-id pub-id-type="publisher-id">EOR-22-0117</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Knee</subject></subj-group><subj-group subj-group-type="specialities"><compound-subject><compound-subject-part content-type="code">knee</compound-subject-part><compound-subject-part content-type="label">Knee</compound-subject-part></compound-subject></subj-group><subj-group subj-group-type="search-keyword"><subject>total joint arthroplasty</subject><subject>total knee arthroplasty</subject><subject>total hip arthroplasty</subject><subject>chronic hepatitis C</subject><subject>postoperative outcomes</subject></subj-group></article-categories><title-group><article-title>A meta-analysis of postoperative outcomes of patients with and without chronic hepatitis C undergoing primary total hip or knee arthroplasty</article-title><alt-title alt-title-type="lrh">Knee</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0003-0212-7892</contrib-id><name name-style="western"><surname>Kohn</surname><given-names initials="MD">Mark D</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wolock</surname><given-names initials="CJ">Charles J</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Poulson</surname><given-names initials="IJ">Isaac J</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fernando</surname><given-names initials="ND">Navin D</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Orthopaedic Surgery and Sports Medicine</institution>, <addr-line>University of Washington, Seattle, Washington, USA</addr-line></aff><aff id="aff2"><label>2</label><institution>Department of Biostatistics</institution>, <addr-line>University of Washington, Seattle, Washington, USA</addr-line></aff><aff id="aff3"><label>3</label><institution>School of Medicine</institution>, <addr-line>University of Washington, Seattle, Washington, USA</addr-line></aff></contrib-group><author-notes><corresp id="cor1">Correspondence should be addressed to M D Kohn; Email: <email>markdkohn@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>4</month><year>2023</year></pub-date><pub-date pub-type="collection"><day>01</day><month>4</month><year>2023</year></pub-date><volume>8</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">434876</issue-id><fpage>180</fpage><lpage>188</lpage><pub-history><event event-type="pmc-release"><date><day>25</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>04</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-16 23:25:13.983"><day>16</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; the author(s)</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>the author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="88x31.jpg"/>This work is licensed under a <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-NonCommercial 4.0 International License.</ext-link>
</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="EOR-22-0117.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="EOR-22-0117.pdf"/><abstract><sec><title>Purpose</title><list list-type="bullet"><list-item><p> This investigation provides a rigorous systematic review of the postoperative outcomes of patients with and without chronic hepatitis C who underwent total hip arthroplasty (THA) and total knee arthroplasty (TKA).</p></list-item></list></sec><sec><title>Methods</title><list list-type="bullet"><list-item><p>We queried PubMed, Embase, Cochrane Database of Systematic Reviews, Scopus, Web of Science and the &#8216;gray&#8217; literature, including supplemental materials, conference abstracts and proceedings as well as commentary published in various peer-reviewed journals from 1992 to present to evaluate studies that compared the postoperative outcomes of patients with and without chronic hepatitis C who underwent primary THA or TKA. This investigation was registered in the PROSPERO international prospective register of systematic reviews and follows the guidelines provided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. In our literature search, we identified 14 articles that met our inclusion criteria and were included in our fixed-effects meta-analysis. The postoperative outcomes analyzed included periprosthetic joint infection (PJI), aseptic revision, non-homebound discharge and inpatient mortality.</p></list-item></list></sec><sec><title>Results</title><list list-type="bullet"><list-item><p>Our statistical analysis demonstrated a statistically significant increase in postoperative complications of patients with chronic hepatitis C who underwent primary THA or TKA including PJI (odds ratio (OR): 1.98, 95% CI: 1.86 &#8211; 2.10), aseptic revision (OR: 1.58, 95% CI: 1.50 &#8211; 1.67), non-homebound discharge (OR: 1.31, 95% CI: 1.28&#8211; 1.34) and inpatient mortality (OR: 9.37, 95% CI: 8.17 &#8211; 10.75).</p></list-item></list></sec><sec><title>Conclusion</title><list list-type="bullet"><list-item><p>This meta-analysis demonstrated a statistically significant increase in adverse postoperative complications in patients with chronic hepatitis C who underwent primary THA or TKA compared to patients without chronic hepatitis C.</p></list-item></list></sec></abstract><kwd-group><title>Keywords</title><kwd>total joint arthroplasty</kwd><kwd>total knee arthroplasty</kwd><kwd>total hip arthroplasty</kwd><kwd>chronic hepatitis C</kwd><kwd>postoperative outcomes</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>ifp:collection</meta-name><meta-value>knee</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec><title>Introduction</title><p>Recent estimates of the prevalence of patients infected with hepatitis C include at least 5.2 million persons living in the United States. (<xref rid="bib1" ref-type="bibr">1</xref>) Patients with chronic hepatitis C who underwent total joint arthroplasty (TJA) have been shown to incur some of the highest costs of care as reflected by reimbursements during the 90-day global period (<xref rid="bib2" ref-type="bibr">2</xref>). With projected annual rates of total hip arthroplasty (THA) and total knee arthroplasty (TKA) expected to increase exponentially to 635 000 and 1.26 million, respectively, by 2030 (<xref rid="bib3" ref-type="bibr">3</xref>), there is increased interest in investigating the modifiable risk factors that may contribute to postoperative complications. Postoperative complications, including periprosthetic joint infection (PJI), can carry significant morbidity to patients and cost the healthcare system hundreds of millions of dollars per year. (<xref rid="bib4" ref-type="bibr">4</xref>) Moreover, TJA requires the manual manipulation of sharp boney surfaces and instruments which can lead to high rates of glove perforation (<xref rid="bib5" ref-type="bibr">5</xref>), leading to the transmission of blood-borne pathogens. As medical innovations have advanced, new medical treatments for chronic hepatitis C have become more affordable and accessible to patients, including &#8216;curative&#8217; modalities. These advances have stimulated interest into the feasibility, practicality and potential benefits of preoperative treatment of hepatitis C prior to undergoing TJA (<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>). More recently, a published meta-analysis of observational studies suggests that anti-viral treatment for chronic hepatitis C is associated with a reduced risk of PJI (<xref rid="bib10" ref-type="bibr">10</xref>).</p><p>Although multiple studies have evaluated the incidence of postoperative complications in patients with hepatitis C undergoing TJA, the majority of the literature consists or institutional data which are of insufficient power to form definitive conclusions. This meta-analysis as such sought to provide a rigorous quantitative analysis of the postoperative complications noted of patients with chronic hepatitis C who underwent elective THA and TKA.</p></sec><sec><title>Methods</title><p>This investigation is registered in the PROSPERO international prospective register of systematic reviews (CRD42019134121). Our investigation followed the guidelines presented by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (<xref rid="bib11" ref-type="bibr">11</xref>).</p><p>This meta-analysis sought to quantitatively investigate the postoperative outcomes of patients with and without chronic hepatitis C who underwent elective THA or TKA. The primary outcome measures used in this analysis include PJI, aseptic revision, non-homebound discharge and inpatient mortality.</p><sec><title>Eligibility criteria</title><p>The population being studied included patients greater than or equal to 18 years of age with chronic hepatitis C as defined by International Classification of Diseases, Clinical Modification (ICD-9-CM) codes 070.54 or 070.70, or positive hepatitis C virus (HCV) core antigen testing, standard immunoassay testing, rapid immunoassay testing, recombinant immunoblot assay testing, positive HCV viral load (VL) or HCV RNA assay testing who underwent TKA or THA. We compared these patients to patients without chronic hepatitis C who underwent TKA or THA. Exclusion criteria included co-infection with human immunodeficiency virus (HIV) or hepatitis B virus (HBV) at the time of surgery. Additionally, we excluded case reports but included observational (retrospective or prospective) studies, case&#8211;control studies and randomized control trial studies in our database search.</p><p>We included patients undergoing elective THA or TKA with or without chronic hepatitis C, as defined by Current Procedural Terminology codes 27447 or 27130 or ICD-9-CM procedure code 84.54.</p></sec><sec><title>Information sources</title><p>The results of our literature search summarized in a PRISMA flow diagram provided in Supplementary Fig. 1 (see section on <xref rid="supp1" ref-type="sec">supplementary materials</xref> given at the end of this article) (<xref rid="bib12" ref-type="bibr">12</xref>). We searched PubMed, EMBASE, Cochrane Database of Systematic Reviews, Scopus, Web of Science and the &#8216;gray&#8217; literature, including the supplemental materials, conference abstracts and proceedings as well as commentary published in <italic toggle="yes">The Journal of Bone and Joint Surgery</italic> (British and American Volumes), <italic toggle="yes">Clinical Orthopaedics and Related Research</italic> and <italic toggle="yes">The Journal of Arthroplasty</italic> in the English language from 1992 to present. The year 1992 was selected as a start date because it was when &#8216;hepatitis C&#8217; was introduced as a MeSH term in PubMed. We used MeSH terms and keyword searches that include &#8216;hepatitis c&#8217;, &#8216;arthroplasty&#8217;, &#8216;total joint arthroplasty&#8217;, &#8216;total knee arthroplasty&#8217;, &#8216;total hip arthroplasty&#8217;, &#8216;outcomes&#8217;, &#8216;total knee replacement&#8217; and &#8216;total hip replacement&#8217;. Please see the <xref rid="supp1" ref-type="sec">supplementary data</xref> for a complete list of search terms for each database queried.</p></sec><sec><title>Study selection</title><p>In order to perform the meta-analysis, we identified 14 studies (<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>) that met our inclusion criteria (see <xref rid="tbl1" ref-type="table">Table 1</xref>). All were retrospective cohort studies.
<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>List of all studies included in the meta-analysis. Note that some studies analyzed TKA and THA separately, so the total sample size reported here does not reflect the sample size of the separate analyses.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Study</th><th align="center" valign="bottom" rowspan="1" colspan="1">Sample size</th><th align="center" valign="bottom" rowspan="1" colspan="1">Study period</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Bendich <italic toggle="yes">et al</italic>. (<xref rid="bib7" ref-type="bibr">7</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">42 268</td><td align="center" valign="top" rowspan="1" colspan="1">2014&#8211;2018</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Best <italic toggle="yes">et al</italic>. (<xref rid="bib13" ref-type="bibr">13</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">8 363 266</td><td align="center" valign="top" rowspan="1" colspan="1">1990&#8211;2007</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cancienne <italic toggle="yes">et al</italic>. (<xref rid="bib14" ref-type="bibr">14</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">218 744</td><td align="center" valign="top" rowspan="1" colspan="1">2005&#8211;2012</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Issa <italic toggle="yes">et al</italic>. (<xref rid="bib15" ref-type="bibr">15</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">25 372</td><td align="center" valign="top" rowspan="1" colspan="1">1998&#8211;2010</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Issa <italic toggle="yes">et al</italic>. (<xref rid="bib16" ref-type="bibr">16</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">216</td><td align="center" valign="top" rowspan="1" colspan="1">2002&#8211;2011</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kildow <italic toggle="yes">et al</italic>. (<xref rid="bib17" ref-type="bibr">17</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">22 663</td><td align="center" valign="top" rowspan="1" colspan="1">2005&#8211;2012</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mahure <italic toggle="yes">et al</italic>. (<xref rid="bib18" ref-type="bibr">18</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">80 722</td><td align="center" valign="top" rowspan="1" colspan="1">2010&#8211;2014</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Novikov <italic toggle="yes">et al</italic>. (<xref rid="bib19" ref-type="bibr">19</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">233</td><td align="center" valign="top" rowspan="1" colspan="1">2005&#8211;2018</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Orozco <italic toggle="yes">et al</italic>. (<xref rid="bib20" ref-type="bibr">20</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">149</td><td align="center" valign="top" rowspan="1" colspan="1">2006&#8211;2011</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pour <italic toggle="yes">et al</italic>. (<xref rid="bib21" ref-type="bibr">21</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">215</td><td align="center" valign="top" rowspan="1" colspan="1">1995&#8211;2006</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Schwarzkopf <italic toggle="yes">et al</italic>. (<xref rid="bib8" ref-type="bibr">8</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">127</td><td align="center" valign="top" rowspan="1" colspan="1">2011&#8211;2018</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bedair <italic toggle="yes">et al</italic>. (<xref rid="bib6" ref-type="bibr">6</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">105</td><td align="center" valign="top" rowspan="1" colspan="1">2006&#8211;2016</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Jergesen <italic toggle="yes">et al</italic>. (<xref rid="bib22" ref-type="bibr">22</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">486</td><td align="center" valign="top" rowspan="1" colspan="1">2008&#8211;2013</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mahure <italic toggle="yes">et al</italic>. (<xref rid="bib23" ref-type="bibr">23</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">137 801</td><td align="center" valign="top" rowspan="1" colspan="1">2010&#8211;2014</td></tr></tbody></table></table-wrap>
</p><p>Some studies included only patients who underwent TKA, others included only patients who underwent THA, and some performed pooled analyses including both surgery types. Since we expect the impact of HCV infection to be heterogeneous across different surgery types, we included results for TKA and THA separately when possible but used the pooled TJA analysis if that was the only result provided by a study. Studies also differed in terms of which patient groups they compared. Most studies compared HCV-infected patients to uninfected patients. However, other studies considered only patients known to be infected with HCV, comparing treated/cured patients to untreated/uncured patients or patients with detectable VL to patients with undetectable VL. We included all of these results in the meta-analysis, since patients who are cured or who have undetectable VL are expected to have similar outcomes to patients with no HCV infection.</p><p>Our outcomes of interest were PJI, aseptic revision surgery, non-homebound discharge status and inpatient mortality. We used odds ratios (ORs) to measure the association between HCV status and each outcome. We used the standard asymptotic normal approximation to construct 95% CIs for the logarithm of the OR and then transformed these into CIs for the OR itself. For some outcomes, there was complete separation, meaning that the outcome event was observed zero times in either the infected or the uninfected group. In this case, we added 1/2 to each observed count (infected with outcome, infected without outcome, uninfected with outcome and uninfected without outcome) and then calculated the OR and CI in the same way as above (<xref rid="bib24" ref-type="bibr">24</xref>).</p></sec><sec><title>Data collection</title><p>The studies included were selected from a larger group that are the result of a search that utilizes the abovementioned MeSH terms and keyword searches in the previously mentioned databases. Two reviewers determined whether the study evaluates patients with chronic hepatitis C who underwent THA or TKA without co-infection with HIV or HBV by consensus. If there was a disagreement among the two reviewers, a third reviewer adjudicated the disagreement. The data extracted included the outcome measures listed previously.</p></sec><sec><title>Statistical analysis</title><p>For each outcome of interest, we performed a fixed-effects meta-analysis. Unlike a traditional &#8216;common-effect&#8217; meta-analysis, the fixed-effects meta-analysis does not assume that all studies estimate a single common association. The fixed-effects approach allows heterogeneity between the studies. We used standard precision weights. We constructed 95% CIs for the pooled estimates using a normal approximation.</p><p>For each analysis, we estimated the between-study heterogeneity in two ways. First, we use the <italic toggle="yes">I</italic>
<sup>2</sup> statistic (<xref rid="bib25" ref-type="bibr">25</xref>). We also used a re-weighted version of Cochran&#8217;s <italic toggle="yes">Q</italic>, as described by Dersimonian and Laird (<xref rid="bib26" ref-type="bibr">26</xref>). This re-weighted <italic toggle="yes">Q</italic> can be interpreted as the estimated standard deviation of the effect sizes around the pooled estimate, weighted by study precision. This is presented on the scale of the logarithm of the OR.</p><p>For the analysis of PJI, where there was a mixture of studies that did and did not address confounding, we performed a fixed-effects meta-regression of the log OR estimate on a binary variable indicating whether a study accounted for confounding. This is equivalent to a standard weighted linear regression with inverse variance weights. We constructed a 95% CI for the regression coefficient using the model-based standard error estimate.</p></sec><sec><title>Risk of bias in individual studies</title><p>In order to investigate the possibility of reporting bias, we produced a funnel plot for each analysis. Asymmetry in the funnel plot can be an indication of reporting bias; in particular, a lack of studies with lower precision and smaller estimated effect sizes may be cause for concern.</p><p>In the 14 studies, there were a variety of approaches to addressing the confounding factors. Some studies performed frequency matching of exposed and unexposed patients, others included possible confounders as regression covariates, and a few studies did not account for confounding. For the purposes of the meta-analysis, we considered a study to have accounted for confounding if it provided estimates from either matched or adjusted analyses. Studies varied in terms of which confounders they included, although most used at least age, sex, diabetes, and obesity or BMI.</p><p>To assess the relationship between the study-specific effect size estimates and study quality, we performed a fixed-effects meta-regression. We estimate that the difference in effect size comparing studies that controlled for confounding to those that did not is &#8211;1.55 (95% CI: -1.70, -1.41) on a logarithmic scale. In other words, we estimate that adjusted/matched ORs are around 79% smaller, on average, than ORs from studies that did not match or adjust for confounders.</p><p>Given this substantial difference, we repeated the fixed-effects meta-analysis including only those studies that attempted to control for confounding. The <italic toggle="yes">I</italic>
<sup>2</sup> is now 20%, and the estimated weighted standard deviation of the effect sizes is 0.07. The overall OR estimate in this case is lower than in the previous analysis.</p></sec></sec><sec><title>Results</title><sec><title>Periprosthetic joint infection</title><p>There were 12 studies that analyzed the association between HCV infection and the risk of PJI (see <xref rid="tbl2" ref-type="table">Table 2</xref>).
<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>List of all studies included in the PJI analysis. Studies without a listed follow-up time or times did not indicate a pre-established amount of follow-up time.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Study</th><th align="center" valign="bottom" rowspan="1" colspan="1">Surgery</th><th align="center" valign="bottom" rowspan="1" colspan="1">Comparison groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">Adjusted/matched?</th><th align="center" valign="bottom" rowspan="1" colspan="1">Follow-up</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Bendich <italic toggle="yes">et al</italic>. (<xref rid="bib7" ref-type="bibr">7</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TKA, THA</td><td align="center" valign="top" rowspan="1" colspan="1">Treated, untreated</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Best <italic toggle="yes">et al</italic>. (<xref rid="bib13" ref-type="bibr">13</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TJA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cancienne <italic toggle="yes">et al</italic>. (<xref rid="bib14" ref-type="bibr">14</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TKA, THA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">3 months, 6 months, 1 year</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Issa <italic toggle="yes">et al</italic>. (<xref rid="bib16" ref-type="bibr">16</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">THA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kildow <italic toggle="yes">et al</italic>. (<xref rid="bib17" ref-type="bibr">17</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TKA, THA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">3 months, 2 years</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mahure <italic toggle="yes">et al</italic>. (<xref rid="bib18" ref-type="bibr">18</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">THA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Novikov <italic toggle="yes">et al</italic>. (<xref rid="bib19" ref-type="bibr">19</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TJA</td><td align="center" valign="top" rowspan="1" colspan="1">Detectable VL, undetectable VL</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Orozco <italic toggle="yes">et al</italic>. (<xref rid="bib20" ref-type="bibr">20</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TKA, THA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pour <italic toggle="yes">et al</italic>. (<xref rid="bib21" ref-type="bibr">21</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TKA, THA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Schwarzkopf <italic toggle="yes">et al</italic>. (<xref rid="bib8" ref-type="bibr">8</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TKA</td><td align="center" valign="top" rowspan="1" colspan="1">Cured, uncured</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bedair <italic toggle="yes">et al</italic>. (<xref rid="bib6" ref-type="bibr">6</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">THA</td><td align="center" valign="top" rowspan="1" colspan="1">Treated, untreated</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mahure <italic toggle="yes">et al</italic>. (<xref rid="bib23" ref-type="bibr">23</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TKA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr></tbody></table></table-wrap>
</p><p>For the meta-analysis, we excluded results comparing treated individuals to uninfected individuals, restricting our analysis to comparisons between treated and untreated individuals. For the study by Bendich <italic toggle="yes">et al</italic>. (<xref rid="bib7" ref-type="bibr">7</xref>) and the study by Cancienne <italic toggle="yes">et al</italic>. (<xref rid="bib14" ref-type="bibr">14</xref>), where multiple follow-up times were analyzed, we included the 90-day outcomes in order to maximize comparability. Within each study, the OR estimates for different follow-up times were quite similar, so we expect this to have little impact on our final results. The results of the fixed-effects meta-analysis are shown in <xref rid="fig1" ref-type="fig">Fig. 1</xref>.
<fig position="float" fig-type="figure" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Forest plot for meta-analysis of the association between chronic HCV infection and risk of PJI, including estimates with and without adjustment/matching. The center of each bar is the study-specific point estimate of the OR, and the bar itself is the associated 95% CI. The bar thickness corresponds to how much weight the study received in the pooled estimate. Study 6: Bendich <italic toggle="yes">et al.</italic> (<xref rid="bib7" ref-type="bibr">7</xref>); Study 9: Best <italic toggle="yes">et al.</italic> (<xref rid="bib13" ref-type="bibr">13</xref>); Study 12: Cancienne <italic toggle="yes">et al.</italic> (<xref rid="bib14" ref-type="bibr">14</xref>); Study 33: Issa <italic toggle="yes">et al.</italic> (<xref rid="bib16" ref-type="bibr">16</xref>); Study 36: Kildow <italic toggle="yes">et al.</italic> (<xref rid="bib17" ref-type="bibr">17</xref>); Study 43: Mahure <italic toggle="yes">et al.</italic> (<xref rid="bib18" ref-type="bibr">18</xref>); Study 50: Novikov <italic toggle="yes">et al.</italic> (<xref rid="bib19" ref-type="bibr">19</xref>); Study 51: Orozco <italic toggle="yes">et al.</italic> (<xref rid="bib20" ref-type="bibr">20</xref>); Study 55: Pour <italic toggle="yes">et al.</italic> (<xref rid="bib21" ref-type="bibr">21</xref>); Study 65: Schwarzkopf <italic toggle="yes">et al.</italic> (<xref rid="bib8" ref-type="bibr">8</xref>); Study 151: Bedair <italic toggle="yes">et al.</italic> (<xref rid="bib6" ref-type="bibr">6</xref>); Study 525: Mahure <italic toggle="yes">et al.</italic> (<xref rid="bib23" ref-type="bibr">23</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="EOR-22-0117fig1.jpg"/></fig>
</p><p>The TJA estimate from Best <italic toggle="yes">et al.</italic> (<xref rid="bib13" ref-type="bibr">13</xref>) and the TKA/THA estimates from Cancienne <italic toggle="yes">et al.</italic> (<xref rid="bib14" ref-type="bibr">14</xref>) have by far the most precision and accordingly receive the heaviest weight in the meta-analysis. The high <italic toggle="yes">I</italic><sup>2</sup> statistic indicates that the vast majority of the uncertainty in the pooled OR is due to inter-study variability. Intuitively, this is supported by the fact that Best <italic toggle="yes">et al</italic>.&#8217;s (<xref rid="bib13" ref-type="bibr">13</xref>) estimate is substantially larger in magnitude than the two estimates reported by Cancienne <italic toggle="yes">et al.</italic> (<xref rid="bib14" ref-type="bibr">14</xref>) , while each of these estimates has high precision. The estimated weighted standard deviation of the effect sizes is 0.69.</p><p>As all the included studies were observational in nature, accounting for confounders (either by matching or regression adjustment) is important. We repeated the fixed-effects meta-analysis including only those studies that attempted to control for confounding. The results of this analysis are shown in <xref rid="fig2" ref-type="fig">Figure 2</xref>. The <italic toggle="yes">I<sup>2</sup></italic> was then 20%, and the estimated weighted standard deviation of the effect sizes was0.07. The overall odds ratio estimate in this case was lower than in the previous analysis. We estimate that the odds of inpatient infection are 1.98 times higher in HCV-infected patients than in uninfected patients (95% CI: 1.86, 2.10).
<fig position="float" fig-type="figure" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Forest plot for meta-analysis of the association between chronic HCV infection and risk of PJI, including only estimates with adjustment/matching. The center of each bar is the study-specific point estimate of the OR, and the bar itself is the associated 95% CI. The bar thickness corresponds to how much weight the study received in the pooled estimate. Study 6: Bendich <italic toggle="yes">et al.</italic> (<xref rid="bib7" ref-type="bibr">7</xref>); Study 12: Cancienne <italic toggle="yes">et al.</italic> (<xref rid="bib14" ref-type="bibr">14</xref>); Study 33: Issa <italic toggle="yes">et al.</italic> (<xref rid="bib16" ref-type="bibr">16</xref>); Study 36: Kildow <italic toggle="yes">et al.</italic> (<xref rid="bib17" ref-type="bibr">17</xref>); Study 50: Novikov <italic toggle="yes">et al.</italic> (<xref rid="bib19" ref-type="bibr">19</xref>); Study 51: Orozco <italic toggle="yes">et al.</italic> (<xref rid="bib20" ref-type="bibr">20</xref>); Study 55: Pour <italic toggle="yes">et al.</italic> (<xref rid="bib21" ref-type="bibr">21</xref>); Study 65: Schwarzkopf <italic toggle="yes">et al.</italic> (<xref rid="bib8" ref-type="bibr">8</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="EOR-22-0117fig2.jpg"/></fig></p><p>The results of the fixed-effects meta-analysis for the risk of PJI are shown in <xref rid="fig1" ref-type="fig">Fig. 1</xref>.</p></sec><sec><title>Aseptic revision</title><p>There were five studies that analyzed the association between HCV infection and the probability of undergoing an aseptic revision surgery (see <xref rid="tbl3" ref-type="table">Table 3</xref>).
<table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>List of all studies included in the revision analysis. Studies without a listed follow-up time or times did not indicate a pre-established amount of follow-up time.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Study</th><th align="center" valign="bottom" rowspan="1" colspan="1">Surgery</th><th align="center" valign="bottom" rowspan="1" colspan="1">Comparison groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">Adjusted/matched?</th><th align="center" valign="bottom" rowspan="1" colspan="1">Follow-up</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Cancienne <italic toggle="yes">et al</italic>. (<xref rid="bib14" ref-type="bibr">14</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TKA, THA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">6 months, 1 year, 2 years, 8 years</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kildow <italic toggle="yes">et al</italic>. (<xref rid="bib17" ref-type="bibr">17</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TKA, THA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">3 months, 2 years</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Novikov <italic toggle="yes">et al</italic>. (<xref rid="bib19" ref-type="bibr">19</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TJA</td><td align="center" valign="top" rowspan="1" colspan="1">Detectable VL, undetectable VL</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Orozco <italic toggle="yes">et al</italic>. (<xref rid="bib20" ref-type="bibr">20</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TKA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pour <italic toggle="yes">et al</italic>. (<xref rid="bib21" ref-type="bibr">21</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TJA, TKA, THA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn><p>VL, viral load.</p></fn></table-wrap-foot></table-wrap>
</p><p>To maximize comparability, for studies with multiple follow-up times, we used only the results from the 2-year follow-up. As with other outcomes, the results for different follow-up times within a study varied little. Pour <italic toggle="yes">et al</italic>. (<xref rid="bib21" ref-type="bibr">21</xref>) included results for both revision and reoperation. We used only revision, since that was the outcome used by all other studies.</p><p>The results of the fixed-effects meta-analysis are shown in <xref rid="fig3" ref-type="fig">Fig. 3</xref>.
<fig position="float" fig-type="figure" id="fig3" orientation="portrait"><label>Figure 3</label><caption><p>Forest plot for meta-analysis of the association between chronic HCV infection and risk of aseptic revision. The center of each bar is the study-specific point estimate of the OR, and the bar itself is the associated 95% CI. The bar thickness corresponds to how much weight the study received in the pooled estimate. Study 12: Cancienne <italic toggle="yes">et al.</italic> (<xref rid="bib14" ref-type="bibr">14</xref>); Study 36: Kildow <italic toggle="yes">et al.</italic> (<xref rid="bib17" ref-type="bibr">17</xref>); Study 50: Novikov <italic toggle="yes">et al.</italic> (<xref rid="bib19" ref-type="bibr">19</xref>); Study 51: Orozco <italic toggle="yes">et al.</italic> (<xref rid="bib20" ref-type="bibr">20</xref>); Study 55: Pour <italic toggle="yes">et al.</italic> (<xref rid="bib21" ref-type="bibr">21</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="EOR-22-0117fig3.jpg"/></fig>
</p><p>The TKA/THA estimates from Cancienne <italic toggle="yes">et al</italic>. (<xref rid="bib14" ref-type="bibr">14</xref>) are the most precise and accordingly receive the heaviest weight in the meta-analysis. The <italic toggle="yes">I</italic>
<sup>2</sup> statistic is relatively low, indicating that heterogeneity is not a major concern. The estimated weighted standard deviation of the effect sizes is also low, around 0.04. The four studies receiving at least 1% weight in the overall OR all provide similar estimates. Overall, we estimate that the odds of revision in HCV-infected patients is 1.58 times as high as in uninfected patients (95% CI: 1.50, 1.67).</p></sec><sec><title>Non-homebound discharge</title><p>There were five studies that analyzed the association between HCV infection and the risk of non-homebound discharge (see <xref rid="tbl4" ref-type="table">Table 4</xref>). Only one of the five studies provided results from an adjusted or matched analysis.
<table-wrap position="float" id="tbl4" orientation="portrait"><label>Table 4</label><caption><p>List of all studies included in the analysis of non-homebound discharge. In all studies, patients were followed until discharge.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Study</th><th align="center" valign="bottom" rowspan="1" colspan="1">Surgery</th><th align="center" valign="bottom" rowspan="1" colspan="1">Comparison groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">Adjusted/matched?</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Best <italic toggle="yes">et al</italic>. (<xref rid="bib13" ref-type="bibr">13</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TKA, THA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mahure <italic toggle="yes">et al</italic>. (<xref rid="bib18" ref-type="bibr">18</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">THA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Novikov <italic toggle="yes">et al</italic>. (<xref rid="bib19" ref-type="bibr">19</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TJA</td><td align="center" valign="top" rowspan="1" colspan="1">Detectable VL, undetectable VL</td><td align="center" valign="top" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Schwarzkopf <italic toggle="yes">et al</italic>. (<xref rid="bib8" ref-type="bibr">8</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TKA</td><td align="center" valign="top" rowspan="1" colspan="1">Cured, uncured</td><td align="center" valign="top" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mahure <italic toggle="yes">et al</italic>. (<xref rid="bib23" ref-type="bibr">23</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TKA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">No</td></tr></tbody></table><table-wrap-foot><fn><p>VL, viral load.</p></fn></table-wrap-foot></table-wrap>
</p><p>The results of the fixed-effects meta-analysis are shown in <xref rid="fig4" ref-type="fig">Fig. 4</xref>.
<fig position="float" fig-type="figure" id="fig4" orientation="portrait"><label>Figure 4</label><caption><p>Forest plot for meta-analysis of the association between chronic HCV infection and risk of non-homebound discharge. The center of each bar is the study-specific point estimate of the OR, and the bar itself is the associated 95% CI. The bar thickness corresponds to how much weight the study received in the pooled estimate. Study 9: Best <italic toggle="yes">et al.</italic> (<xref rid="bib13" ref-type="bibr">13</xref>); Study 43: Mahure <italic toggle="yes">et al.</italic> (<xref rid="bib18" ref-type="bibr">18</xref>); Study 50: Novikov <italic toggle="yes">et al.</italic> (<xref rid="bib19" ref-type="bibr">19</xref>); Study 65: Schwarzkopf <italic toggle="yes">et al.</italic> (<xref rid="bib8" ref-type="bibr">8</xref>); Study 525: Mahure <italic toggle="yes">et al.</italic> (<xref rid="bib23" ref-type="bibr">23</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="EOR-22-0117fig4.jpg"/></fig>
</p><p>The estimates from Best <italic toggle="yes">et al</italic>. (<xref rid="bib13" ref-type="bibr">13</xref>) have a high level of precision compared to the others and accordingly receive the vast majority of the weight in the overall estimate. The <italic toggle="yes">I</italic>
<sup>2</sup> statistic is high, and the estimated weighted standard deviation of the effect sizes is also large, at around 0.32. These indicate a statistically significant degree of heterogeneity. This could be due, at least in part, to the fact that four of the five studies did not attempt to control for confounding. We would therefore expect the resulting estimates to reflect the characteristics of the study-specific patient population. Overall, we estimate that the odds of non-homebound discharge in HCV-infected patients are 1.31 times as high as in uninfected patients (95% CI: 1.28, 1.34).</p></sec><sec><title>Inpatient mortality</title><p>There were three studies that analyzed the association between HCV infection and the risk of inpatient mortality (see <xref rid="tbl5" ref-type="table">Table 5</xref>). Only one of the three studies provided results from an adjusted or matched analysis.
<table-wrap position="float" id="tbl5" orientation="portrait"><label>Table 5</label><caption><p>List of all studies included in the analysis of inpatient mortality. In all studies, patients were followed until discharge or death.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Study</th><th align="center" valign="bottom" rowspan="1" colspan="1">Surgery</th><th align="center" valign="bottom" rowspan="1" colspan="1">Comparison groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">Adjusted/matched?</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Mahure <italic toggle="yes">et al</italic>. (<xref rid="bib18" ref-type="bibr">18</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">THA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Schwarzkopf <italic toggle="yes">et al</italic>. (<xref rid="bib8" ref-type="bibr">8</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TKA</td><td align="center" valign="top" rowspan="1" colspan="1">Cured, uncured</td><td align="center" valign="top" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mahure <italic toggle="yes">et al</italic>. (<xref rid="bib23" ref-type="bibr">23</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">TKA</td><td align="center" valign="top" rowspan="1" colspan="1">Infected, uninfected</td><td align="center" valign="top" rowspan="1" colspan="1">No</td></tr></tbody></table></table-wrap>
</p><p>The results of the fixed-effects meta-analysis are shown in <xref rid="fig5" ref-type="fig">Fig. 5</xref>.
<fig position="float" fig-type="figure" id="fig5" orientation="portrait"><label>Figure 5</label><caption><p>Forest plot for meta-analysis of the association between chronic HCV infection and risk of inpatient mortality. The center of each bar is the study-specific point estimate of the OR, and the bar itself is the associated 95% CI. The bar thickness corresponds to how much weight the study received in the pooled estimate. Study 43: Mahure <italic toggle="yes">et al.</italic> (<xref rid="bib18" ref-type="bibr">18</xref>); Study 65: Schwarzkopf <italic toggle="yes">et al.</italic> (<xref rid="bib8" ref-type="bibr">8</xref>); Study 525: Mahure <italic toggle="yes">et al.</italic> (<xref rid="bib23" ref-type="bibr">23</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="EOR-22-0117fig5.jpg"/></fig>
</p><p>The estimates from Mahure <italic toggle="yes">et al</italic>. (<xref rid="bib18" ref-type="bibr">18</xref>) have a high level of precision compared to the others and carry almost all of the weight in the overall estimate. The <italic toggle="yes">I</italic>
<sup>2</sup> statistic is low, although the estimated weighted standard deviation of the effect sizes is fairly substantial (0.29). Only one of the three studies give only adjusted estimates. Overall, we estimate that the odds of inpatient mortality in HCV-infected patients are 9.37 times as high as in uninfected patients (95% CI: 8.17, 10.75). We note that the results of Mahure <italic toggle="yes">et al</italic>. (<xref rid="bib18" ref-type="bibr">18</xref>) are somewhat unusual; the estimated effect size is extremely large and precise, but the study reports a <italic toggle="yes">P</italic>-value that is only marginally significant (0.044). Furthermore, in attempting to reconstruct the standard error of the point estimate using the reported CI, we found that the interval is asymmetric about the point estimate on the logarithm scale. We would expect approximate symmetry in this scenario. Due to these concerns, we repeated the mortality analysis removing study 43. The results are shown in Supplementary Fig. 2. As expected, after excluding the study by Mahure <italic toggle="yes">et al</italic>. (<xref rid="bib18" ref-type="bibr">18</xref>), the estimated association is substantially lower (OR: 2.62), with low precision.</p><p>Supplementary Figure 3 demonstrates the funnel plot for the PJI analysis with only studies that adjusted/matched. The funnel plot suggests there may be some publication bias due to the lack of studies with low precision and small effect size, although there are also few studies with low precision and large effect size. Supplementary Figure 4 demonstrates the funnel plot for the aseptic revision analysis. The asymmetric funnel plot suggests the presence of publication bias or some systematic difference between high- and low-precision studies. Supplementary Figure 5 demonstrates the funnel plot for the non-homebound discharge analysis. Due to the relatively small number of studies, and the general lack of control for confounding, it is difficult to interpret the funnel plot in this instance. Supplementary Figure 5 demonstrates the funnel plot for the inpatient mortality analysis. With only three studies, interpretation is difficult.</p></sec></sec><sec><title>Discussion</title><p>Based on the meta-analysis we performed, we found a statistically significant increased risk of adverse postoperative outcomes comparing HCV-infected and uninfected patients undergoing TJA. For all outcomes, we see substantial heterogeneity when including both unadjusted estimates and adjusted estimates, as is expected, given that none of the studies were randomized. For the PJI and aseptic revision outcomes, where there are a sufficient number of adjusted estimates to exclude the unadjusted estimates, we observe relatively low heterogeneity. This was somewhat unexpected given that we included analyses of both TKA and THA. There was extreme heterogeneity in the analysis of non-homebound discharge, but a formal analysis of differences between adjusted and unadjusted estimates was not possible as only a single adjusted estimate was available. For mortality, there are only three studies to analyze, one with much more precision than the other two. Since this analysis primarily reflects the results of one study, the estimated heterogeneity is low.</p><p>Overall, a few studies dominate the pooled estimates. This is unsurprising given the wide range of sample size, and therefore precision, in the available studies. The validity of the meta-analysis is not affected by this, but it is an important factor in our interpretation of the results. In particular, fixed-effects meta-analysis estimates a precision-weighted average of the effect sizes in the included studies. Because of this, our estimates largely reflect the association between HCV infection and negative postoperative outcomes in the target populations of the large, high-precision studies. If these populations are representative of our population of interest, then there is no issue. For example, in the analysis of PJI (adjusted estimates only), over 99% of the weight is placed on the studies by Cancienne <italic toggle="yes">et al.</italic> (<xref rid="bib14" ref-type="bibr">14</xref>) and Kildow <italic toggle="yes">et al</italic>. (<xref rid="bib17" ref-type="bibr">17</xref>). Both of these studies sampled individuals from Medicare databases; our pooled OR estimate of 1.98 reflects the increased risk of PJI comparing HCV-infected to uninfected patients in the population of Medicare recipients. If we were primarily interested in younger patients, this could be cause for concern.</p><p>The meta-regression in the PJI analysis shows a substantial difference in effect size estimates between studies that did and did not account for confounding via matching or regression adjustment. As with the pooled OR estimates, this result reflects differences in this particular collection of studies; it does not necessarily predict differences between hypothetical future studies. Nonetheless, confounding is always a concern in observational studies, and we expect adjusted estimates to be less susceptible to bias.</p><p>There was a wide range of reported sample sizes, from 105 to over 8 million. The study by Best <italic toggle="yes">et al</italic>. (<xref rid="bib13" ref-type="bibr">13</xref>) was the largest and used data from the National Hospital Discharge Survey. This data source comprised of a random sample of hospital discharges from non-federal short-stay hospitals in the USA. This random sample represents around 1% of all US hospital discharges. (<xref rid="bib27" ref-type="bibr">27</xref>) The Survey produces a weighted sample, meant to represent all discharges in the USA. It is possible that Best <italic toggle="yes">et al</italic>. (<xref rid="bib13" ref-type="bibr">13</xref>) study&#8217;s reported sample size of 8 million represents all TJA surgeries in the weighted sample rather than the unweighted (raw) sample. This is not made clear in the study. Given that the Survey contains around 1% of all hospital discharges, and around 1 million TJA surgeries are performed each year in the USA (<xref rid="bib28" ref-type="bibr">28</xref>), it is unlikely that the Best <italic toggle="yes">et al</italic>. (<xref rid="bib13" ref-type="bibr">13</xref>) study actually has 8 million directly observed surgeries over its 18-year duration. It is more likely that a smaller number of observed surgeries were reweighted to create a representative sample of 8 million surgeries. Consequently, we believe it is unlikely that there is substantial overlap between the Best <italic toggle="yes">et al</italic>. (<xref rid="bib13" ref-type="bibr">13</xref>) and other studies.</p></sec><sec><title>Conclusion</title><p>This meta-analysis is the first quantitative analysis registered in the PROSPERO international database of systematic reviews to evaluate the postoperative outcomes of patients with and without chronic hepatitis C who underwent total hip and total knee arthroplasty. A parallel meta-analysis of adverse outcomes in patients with chronic hepatitis C undergoing total joint arthroplasty was performed by investigators in the People&#8217;s Republic of China with access to the China National Knowledge Infrastructure (<xref rid="bib29" ref-type="bibr">29</xref>). Our quantitative analysis suggests that patients with chronic hepatitis C are more likely to experience adverse postoperative complications including PJI, aseptic revision, non-homebound discharge and inpatient mortality. We found that HCV infection was positively associated with all four outcomes, with estimated ORs of 1.98, 1.58, 1.31 and 9.37, respectively. For non-homebound discharge and inpatient mortality, most of the available studies did not account for potential confounders by patient demographic and health characteristics, which could limit the generalizability of the results. This analysis suggests that future investigations should be undertaken to develop potential preoperative protocols that incorporate treatment of HCV prior to undergoing elective total joint arthroplasty. These investigations will likely need to include a cost&#8211;benefit analysis of preoperative HCV treatment and determine its feasibility in everyday clinical practice. Access to healthcare resources and ethical implications of delayed surgical treatment to pursue medical risk modification must also be considered in this discussion.</p></sec><sec sec-type="supplementary-material" id="supp1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><caption><title>Supplementary Figure 1 PRISMA Flow Diagram.</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="EOR-22-0117supplementary_figure_1.pdf" id="d64e1473" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD2" position="float" content-type="local-data" orientation="portrait"><caption><title>Supplementary Figure 2: Funnel plot for meta-analysis of the association between chronic HCV infection and risk of PJI. Each point represents a single point estimate, with the odds ratio on the x-axis and the standard error (on the logarithm scale) on the y-axis. The center dashed line is the pooled odds ratio estimate. The diagonal dashed lines outline a pseudo-confidence region, equal to the point estimate plus or minus the standard error on the y-axis.</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="EOR-22-0117supplementary_figure_2.pdf" id="d64e1477" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD3" position="float" content-type="local-data" orientation="portrait"><caption><title>Supplementary Figure 3: Funnel plot for meta-analysis of the association between chronic HCV infection and risk of asceptic revision. Each point represents a single point estimate, with the odds ratio on the x-axis and the standard error (on the logarithm scale) on the y-axis. The center dashed line is the pooled odds ratio estimate. The diagonal dashed lines outline a pseudo-confidence region, equal to the point estimate plus or minus the standard error on the y-axis.</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="EOR-22-0117supplementary_figure_3.pdf" id="d64e1481" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD4" position="float" content-type="local-data" orientation="portrait"><caption><title>Supplementary Figure 4: Funnel plot for meta-analysis of the association between chronic HCV infection and risk of non-homebound discharge. Each point represents a single point estimate, with the odds ratio on the x-axis and the standard error (on the logarithm scale) on the y-axis. The center dashed line is the pooled odds ratio estimate. The diagonal dashed lines outline a pseudo-confidence region, equal to the point estimate plus or minus the standard error on the y-axis.</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="EOR-22-0117supplementary_figure_4.pdf" id="d64e1485" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD5" position="float" content-type="local-data" orientation="portrait"><caption><title>Supplementary Figure 5: Funnel plot for meta-analysis of the association between chronic HCV infection and risk of inpatient mortality. Each point represents a single point estimate, with the odds ratio on the x-axis and the standard error (on the logarithm scale) on the y-axis. The center dashed line is the pooled odds ratio estimate. The diagonal dashed lines outline a pseudo-confidence region, equal to the point estimate plus or minus the standard error on the y-axis.</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="EOR-22-0117supplementary_figure_5.pdf" id="d64e1489" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD6" position="float" content-type="local-data" orientation="portrait"><caption><title>Supplementary Material</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="EOR-22-0117supplementary_material.pdf" id="d64e1493" position="anchor" orientation="portrait"/></supplementary-material></sec><sec sec-type="COI-statement"><title>ICMJE conflict of interest statement</title><p>The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.</p></sec><sec><title>Funding</title><p>This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.</p></sec></body><back><ref-list><title>References</title><ref id="bib1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chak</surname><given-names>E</given-names></name><name name-style="western"><surname>Talal</surname><given-names>AH</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>KE</given-names></name><name name-style="western"><surname>Schiff</surname><given-names>ER</given-names></name> &amp; <name name-style="western"><surname>Saab</surname><given-names>S</given-names></name></person-group>. <article-title>Hepatitis C virus infection in USA: an estimate of true prevalence</article-title>. <source>Liver International</source><year>2011</year><volume>31</volume><fpage>1090</fpage>&#8211;<lpage>1101</lpage>. (<pub-id pub-id-type="doi">10.1111/j.1478-3231.2011.02494.x</pub-id>)<pub-id pub-id-type="pmid">21745274</pub-id></mixed-citation></ref><ref id="bib2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosas</surname><given-names>S</given-names></name><name name-style="western"><surname>Sabeh</surname><given-names>KG</given-names></name><name name-style="western"><surname>Buller</surname><given-names>LT</given-names></name><name name-style="western"><surname>Law</surname><given-names>TY</given-names></name><name name-style="western"><surname>Roche</surname><given-names>MW</given-names></name> &amp; <name name-style="western"><surname>Hernandez</surname><given-names>VH</given-names></name></person-group>. <article-title>Medical comorbidities impact the episode-of-care reimbursements of total hip arthroplasty</article-title>. <source>Journal of Arthroplasty</source><year>2017</year><volume>32</volume><fpage>2082</fpage>&#8211;<lpage>2087</lpage>. (<pub-id pub-id-type="doi">10.1016/j.arth.2017.02.039</pub-id>)<pub-id pub-id-type="pmid">28318861</pub-id></mixed-citation></ref><ref id="bib3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sloan</surname><given-names>M</given-names></name><name name-style="western"><surname>Premkumar</surname><given-names>A</given-names></name> &amp; <name name-style="western"><surname>Sheth</surname><given-names>NP</given-names></name></person-group>. <article-title>Projected volume of primary total joint arthroplasty in the U.S., 2014 to 2030</article-title>. <source>Journal of Bone and Joint Surgery. American Volume</source><year>2018</year><volume>100</volume><fpage>1455</fpage>&#8211;<lpage>1460</lpage>. (<pub-id pub-id-type="doi">10.2106/JBJS.17.01617</pub-id>)<pub-id pub-id-type="pmid">30180053</pub-id></mixed-citation></ref><ref id="bib4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurtz</surname><given-names>SM</given-names></name><name name-style="western"><surname>Lau</surname><given-names>E</given-names></name><name name-style="western"><surname>Watson</surname><given-names>H</given-names></name><name name-style="western"><surname>Schmier</surname><given-names>JK</given-names></name> &amp; <name name-style="western"><surname>Parvizi</surname><given-names>J</given-names></name></person-group>. <article-title>Economic burden of periprosthetic joint infection in the United States</article-title>. <source>Journal of Arthroplasty</source><year>2012</year><volume>27</volume>(<issue>8</issue>)(<issue>Supplement</issue>) <fpage>61</fpage>&#8211;<lpage>5.e1</lpage>. (<pub-id pub-id-type="doi">10.1016/j.arth.2012.02.022</pub-id>)<pub-id pub-id-type="pmid">22554729</pub-id></mixed-citation></ref><ref id="bib5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demircay</surname><given-names>E</given-names></name><name name-style="western"><surname>Unay</surname><given-names>K</given-names></name><name name-style="western"><surname>Bilgili</surname><given-names>MG</given-names></name> &amp; <name name-style="western"><surname>Alataca</surname><given-names>G</given-names></name></person-group>. <article-title>Glove perforation in hip and knee arthroplasty</article-title>. <source>Journal of Orthopaedic Science</source><year>2010</year><volume>15</volume><fpage>790</fpage>&#8211;<lpage>794</lpage>. (<pub-id pub-id-type="doi">10.1007/s00776-010-1547-0</pub-id>)<pub-id pub-id-type="pmid">21116897</pub-id></mixed-citation></ref><ref id="bib6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bedair</surname><given-names>HS</given-names></name><name name-style="western"><surname>Schurko</surname><given-names>BM</given-names></name><name name-style="western"><surname>Dwyer</surname><given-names>MK</given-names></name><name name-style="western"><surname>Novikov</surname><given-names>D</given-names></name><name name-style="western"><surname>Anoushiravani</surname><given-names>AA</given-names></name> &amp; <name name-style="western"><surname>Schwarzkopf</surname><given-names>R</given-names></name></person-group>. <article-title>Treatment for chronic hepatitis C prior to total hip arthroplasty significantly reduces periprosthetic joint infection</article-title>. <source>Journal of Arthroplasty</source><year>2019</year><volume>34</volume><fpage>132</fpage>&#8211;<lpage>135</lpage>. (<pub-id pub-id-type="doi">10.1016/j.arth.2018.09.036</pub-id>)<pub-id pub-id-type="pmid">30337253</pub-id></mixed-citation></ref><ref id="bib7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bendich</surname><given-names>I</given-names></name><name name-style="western"><surname>Takemoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>JT</given-names></name><name name-style="western"><surname>Monto</surname><given-names>A</given-names></name><name name-style="western"><surname>Barber</surname><given-names>TC</given-names></name> &amp; <name name-style="western"><surname>Kuo</surname><given-names>AC</given-names></name></person-group>. <article-title>Preoperative treatment of hepatitis C is associated with lower prosthetic joint infection rates in US veterans</article-title>. <source>Journal of Arthroplasty</source><year>2019</year><volume>34</volume><fpage>S319</fpage>&#8211;<lpage>S326.e1</lpage>. (<pub-id pub-id-type="doi">10.1016/j.arth.2019.02.052</pub-id>)<pub-id pub-id-type="pmid">30930157</pub-id></mixed-citation></ref><ref id="bib8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarzkopf</surname><given-names>R</given-names></name><name name-style="western"><surname>Novikov</surname><given-names>D</given-names></name><name name-style="western"><surname>Anoushiravani</surname><given-names>AA</given-names></name><name name-style="western"><surname>Feng</surname><given-names>JE</given-names></name><name name-style="western"><surname>Vigdorchik</surname><given-names>J</given-names></name><name name-style="western"><surname>Schurko</surname><given-names>B</given-names></name><name name-style="western"><surname>Dwyer</surname><given-names>MK</given-names></name> &amp; <name name-style="western"><surname>Bedair</surname><given-names>HS</given-names></name></person-group>. <article-title>The preoperative management of hepatitis C may improve the outcome after total knee arthroplasty</article-title>. <source>Bone and Joint Journal</source><year>2019</year><volume>101&#8211;B</volume><fpage>667</fpage>&#8211;<lpage>674</lpage>. (<pub-id pub-id-type="doi">10.1302/0301-620X.101B6.BJJ-2018-0723.R3</pub-id>)<pub-id pub-id-type="pmid">31154838</pub-id></mixed-citation></ref><ref id="bib9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cornell</surname><given-names>E</given-names></name><name name-style="western"><surname>Novikov</surname><given-names>D</given-names></name><name name-style="western"><surname>Niu</surname><given-names>R</given-names></name><name name-style="western"><surname>Staatz</surname><given-names>K</given-names></name><name name-style="western"><surname>Schwarzkopf</surname><given-names>R</given-names></name> &amp; <name name-style="western"><surname>Smith</surname><given-names>EL</given-names></name></person-group>. <article-title>Hepatitis C antiviral treatment decreases all-cause complications after total joint arthroplasty regardless of the presence of fibrosis</article-title>. <source>Journal of Arthroplasty</source><year>2021</year><volume>36</volume><fpage>1551</fpage>&#8211;<lpage>1555</lpage>. (<pub-id pub-id-type="doi">10.1016/j.arth.2020.12.025</pub-id>)<pub-id pub-id-type="pmid">33431189</pub-id></mixed-citation></ref><ref id="bib10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>T</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ding</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name> &amp; <name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name></person-group>. <article-title>Antiviral treatment for hepatitis C is associated with a reduced risk of periprosthetic joint infection: A meta-analysis of observational studies</article-title>. <source>Journal of Arthroplasty</source><year>2022</year><volume>37</volume><fpage>1870</fpage>&#8211;<lpage>1878</lpage>. (<pub-id pub-id-type="doi">10.1016/j.arth.2022.04.027</pub-id>)<pub-id pub-id-type="pmid">35483609</pub-id></mixed-citation></ref><ref id="bib11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name><name name-style="western"><surname>Liberati</surname><given-names>A</given-names></name><name name-style="western"><surname>Tetzlaff</surname><given-names>J</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name></person-group> &amp; <collab>PRISMA Group</collab>. <article-title>Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement</article-title>. <source>PLOS Medicine</source><year>2009</year><volume>6</volume> e1000097. (<pub-id pub-id-type="doi">10.1371/journal.pmed.1000097</pub-id>)<pub-id pub-id-type="pmcid">PMC2707599</pub-id><pub-id pub-id-type="pmid">19621072</pub-id></mixed-citation></ref><ref id="bib12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>MJ</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>JE</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></name><name name-style="western"><surname>Boutron</surname><given-names>I</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>TC</given-names></name><name name-style="western"><surname>Mulrow</surname><given-names>CD</given-names></name><name name-style="western"><surname>Shamseer</surname><given-names>L</given-names></name><name name-style="western"><surname>Tetzlaff</surname><given-names>JM</given-names></name><name name-style="western"><surname>Akl</surname><given-names>EA</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>SE</given-names></name></person-group>, <etal/><article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title>. <source>BMJ</source><year>2021</year><volume>372</volume> n71. (<pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id>)<pub-id pub-id-type="pmcid">PMC8005924</pub-id><pub-id pub-id-type="pmid">33782057</pub-id></mixed-citation></ref><ref id="bib13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Best</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Buller</surname><given-names>LT</given-names></name><name name-style="western"><surname>Klika</surname><given-names>AK</given-names></name> &amp; <name name-style="western"><surname>Barsoum</surname><given-names>WK</given-names></name></person-group>. <article-title>Increase in perioperative complications following primary total hip and knee arthroplasty in patients with hepatitis C without cirrhosis</article-title>. <source>Journal of Arthroplasty</source><year>2015</year><volume>30</volume><fpage>663</fpage>&#8211;<lpage>668</lpage>. (<pub-id pub-id-type="doi">10.1016/j.arth.2014.11.013</pub-id>)<pub-id pub-id-type="pmid">25492245</pub-id></mixed-citation></ref><ref id="bib14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cancienne</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kandahari</surname><given-names>AM</given-names></name><name name-style="western"><surname>Casp</surname><given-names>A</given-names></name><name name-style="western"><surname>Novicoff</surname><given-names>W</given-names></name><name name-style="western"><surname>Browne</surname><given-names>JA</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Q</given-names></name> &amp; <name name-style="western"><surname>Werner</surname><given-names>BC</given-names></name></person-group>. <article-title>Complication rates after total hip and knee arthroplasty in patients with hepatitis C compared with matched control patients</article-title>. <source>Journal of the American Academy of Orthopaedic Surgeons</source><year>2017</year><volume>25</volume><fpage>e275</fpage>&#8211;<lpage>e281</lpage>. (<pub-id pub-id-type="doi">10.5435/JAAOS-D-16-00920</pub-id>)<pub-id pub-id-type="pmid">29176506</pub-id></mixed-citation></ref><ref id="bib15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Issa</surname><given-names>K</given-names></name><name name-style="western"><surname>Boylan</surname><given-names>MR</given-names></name><name name-style="western"><surname>Naziri</surname><given-names>Q</given-names></name><name name-style="western"><surname>Perfetti</surname><given-names>DC</given-names></name><name name-style="western"><surname>Maheshwari</surname><given-names>AV</given-names></name> &amp; <name name-style="western"><surname>Mont</surname><given-names>MA</given-names></name></person-group>. <article-title>The impact of hepatitis C on short-term outcomes of total joint arthroplasty</article-title>. <source>Journal of Bone and Joint Surgery. American Volume</source><year>2015</year><volume>97</volume><fpage>1952</fpage>&#8211;<lpage>1957</lpage>. (<pub-id pub-id-type="doi">10.2106/JBJS.O.00183</pub-id>)<pub-id pub-id-type="pmid">26631996</pub-id></mixed-citation></ref><ref id="bib16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Issa</surname><given-names>K</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>TP</given-names></name><name name-style="western"><surname>Harwin</surname><given-names>SF</given-names></name><name name-style="western"><surname>Scillia</surname><given-names>AJ</given-names></name><name name-style="western"><surname>McInerney</surname><given-names>VK</given-names></name> &amp; <name name-style="western"><surname>Mont</surname><given-names>MA</given-names></name></person-group>. <article-title>Does hepatitis C affect the clinical and patient-reported outcomes of primary total hip arthroplasty at midterm follow-up?</article-title><source>Journal of Arthroplasty</source><year>2017</year><volume>32</volume><fpage>2779</fpage>&#8211;<lpage>2782</lpage>. (<pub-id pub-id-type="doi">10.1016/j.arth.2017.04.001</pub-id>)<pub-id pub-id-type="pmid">28478187</pub-id></mixed-citation></ref><ref id="bib17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kildow</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Politzer</surname><given-names>CS</given-names></name><name name-style="western"><surname>DiLallo</surname><given-names>M</given-names></name><name name-style="western"><surname>Bolognesi</surname><given-names>MP</given-names></name> &amp; <name name-style="western"><surname>Seyler</surname><given-names>TM</given-names></name></person-group>. <article-title>Short and long-term postoperative complications following total joint arthroplasty in patients with human immunodeficiency virus, hepatitis B, or hepatitis C</article-title>. <source>Journal of Arthroplasty</source><year>2018</year><volume>33</volume><fpage>S86</fpage>&#8211;<lpage>S92.e1</lpage>. (<pub-id pub-id-type="doi">10.1016/j.arth.2017.10.061</pub-id>)<pub-id pub-id-type="pmid">29198873</pub-id></mixed-citation></ref><ref id="bib18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahure</surname><given-names>SA</given-names></name><name name-style="western"><surname>Bosco</surname><given-names>JA</given-names></name><name name-style="western"><surname>Slover</surname><given-names>JD</given-names></name><name name-style="western"><surname>Vigdorchik</surname><given-names>J</given-names></name><name name-style="western"><surname>Iorio</surname><given-names>R</given-names></name> &amp; <name name-style="western"><surname>Schwarzkopf</surname><given-names>R</given-names></name></person-group>. <article-title>Risk of complications after THA increases among patients who are coinfected with HIV and hepatitis C</article-title>. <source>Clinical Orthopaedics and Related Research</source><year>2018</year><volume>476</volume><fpage>356</fpage>&#8211;<lpage>369</lpage>. (<pub-id pub-id-type="doi">10.1007/s11999.0000000000000025</pub-id>)<pub-id pub-id-type="pmid">29529669</pub-id><pub-id pub-id-type="pmcid">PMC6259695</pub-id></mixed-citation></ref><ref id="bib19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Novikov</surname><given-names>D</given-names></name><name name-style="western"><surname>Feng</surname><given-names>JE</given-names></name><name name-style="western"><surname>Anoushiravani</surname><given-names>AA</given-names></name><name name-style="western"><surname>Vigdorchik</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lajam</surname><given-names>CM</given-names></name><name name-style="western"><surname>Seyler</surname><given-names>TM</given-names></name> &amp; <name name-style="western"><surname>Schwarzkopf</surname><given-names>R</given-names></name></person-group>. <article-title>Undetectable hepatitis C viral load is associated with improved outcomes following total joint arthroplasty</article-title>. <source>Journal of Arthroplasty</source><year>2019</year><volume>34</volume><fpage>2890</fpage>&#8211;<lpage>2897</lpage>. (<pub-id pub-id-type="doi">10.1016/j.arth.2019.06.058</pub-id>)<pub-id pub-id-type="pmid">31351854</pub-id></mixed-citation></ref><ref id="bib20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orozco</surname><given-names>F</given-names></name><name name-style="western"><surname>Post</surname><given-names>ZD</given-names></name><name name-style="western"><surname>Baxi</surname><given-names>O</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A</given-names></name> &amp; <name name-style="western"><surname>Ong</surname><given-names>A</given-names></name></person-group>. <article-title>Fibrosis in hepatitis C patients predicts complications after elective total joint arthroplasty</article-title>. <source>Journal of Arthroplasty</source><year>2014</year><volume>29</volume><fpage>7</fpage>&#8211;<lpage>10</lpage>. (<pub-id pub-id-type="doi">10.1016/j.arth.2013.03.023</pub-id>)<pub-id pub-id-type="pmid">23648106</pub-id></mixed-citation></ref><ref id="bib21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pour</surname><given-names>AE</given-names></name><name name-style="western"><surname>Matar</surname><given-names>WY</given-names></name><name name-style="western"><surname>Jafari</surname><given-names>SM</given-names></name><name name-style="western"><surname>Purtill</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Austin</surname><given-names>MS</given-names></name> &amp; <name name-style="western"><surname>Parvizi</surname><given-names>J</given-names></name></person-group>. <article-title>Total joint arthroplasty in patients with hepatitis C</article-title>. <source>Journal of Bone and Joint Surgery. American Volume</source><year>2011</year><volume>93</volume><fpage>1448</fpage>&#8211;<lpage>1454</lpage>. (<pub-id pub-id-type="doi">10.2106/JBJS.J.00219</pub-id>)<pub-id pub-id-type="pmid">21915551</pub-id></mixed-citation></ref><ref id="bib22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jergesen</surname><given-names>HE</given-names></name><name name-style="western"><surname>Thielen</surname><given-names>ZP</given-names></name><name name-style="western"><surname>Roever</surname><given-names>JA</given-names></name><name name-style="western"><surname>Vashon</surname><given-names>TT</given-names></name><name name-style="western"><surname>Wu</surname><given-names>HH</given-names></name> &amp; <name name-style="western"><surname>Yi</surname><given-names>PH</given-names></name></person-group>. <article-title>Primary hip and knee arthroplasty in a safety net hospital: substance abuse and other factors affecting short-term complications</article-title>. <source>Journal of Arthroplasty</source><year>2018</year><volume>33</volume><fpage>3003</fpage>&#8211;<lpage>3008</lpage>. (<pub-id pub-id-type="doi">10.1016/j.arth.2018.05.007</pub-id>)<pub-id pub-id-type="pmid">29853309</pub-id></mixed-citation></ref><ref id="bib23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahure</surname><given-names>SA</given-names></name><name name-style="western"><surname>Bosco</surname><given-names>JA</given-names></name><name name-style="western"><surname>Slover</surname><given-names>JD</given-names></name><name name-style="western"><surname>Vigdorchik</surname><given-names>JM</given-names></name><name name-style="western"><surname>Iorio</surname><given-names>R</given-names></name> &amp; <name name-style="western"><surname>Schwarzkopf</surname><given-names>R</given-names></name></person-group>. <article-title>Coinfection with hepatitis C and HIV is a risk factor for poor outcomes after total knee arthroplasty</article-title>. <source>JB &amp; JS Open Access</source><year>2017</year><volume>2</volume> e0009. (<pub-id pub-id-type="doi">10.2106/JBJS.OA.17.00009</pub-id>)<pub-id pub-id-type="pmcid">PMC6133098</pub-id><pub-id pub-id-type="pmid">30229221</pub-id></mixed-citation></ref><ref id="bib24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sweeting</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>AJ</given-names></name> &amp; <name name-style="western"><surname>Lambert</surname><given-names>PC</given-names></name></person-group>. <article-title>What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data</article-title>. <source>Statistics in Medicine</source><year>2004</year><volume>23</volume><fpage>1351</fpage>&#8211;<lpage>1375</lpage>. (<pub-id pub-id-type="doi">10.1002/sim.1761</pub-id>)<pub-id pub-id-type="pmid">15116347</pub-id></mixed-citation></ref><ref id="bib25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higgins</surname><given-names>JPT</given-names></name> &amp; <name name-style="western"><surname>Thompson</surname><given-names>SG</given-names></name></person-group>. <article-title>Quantifying heterogeneity in a meta-analysis</article-title>. <source>Statistics in Medicine</source><year>2002</year><volume>21</volume><fpage>1539</fpage>&#8211;<lpage>1558</lpage>. (<pub-id pub-id-type="doi">10.1002/sim.1186</pub-id>)<pub-id pub-id-type="pmid">12111919</pub-id></mixed-citation></ref><ref id="bib26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DerSimonian</surname><given-names>R</given-names></name> &amp; <name name-style="western"><surname>Laird</surname><given-names>N</given-names></name></person-group>. <article-title>Meta-analysis in clinical trials</article-title>. <source>Controlled Clinical Trials</source><year>1986</year><volume>7</volume><fpage>177</fpage>&#8211;<lpage>188</lpage>. (<pub-id pub-id-type="doi">10.1016/0197-2456(8690046-2</pub-id>)<pub-id pub-id-type="pmid">3802833</pub-id></mixed-citation></ref><ref id="bib27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bekkers</surname><given-names>S</given-names></name><name name-style="western"><surname>Bot</surname><given-names>AGJ</given-names></name><name name-style="western"><surname>Makarawung</surname><given-names>D</given-names></name><name name-style="western"><surname>Neuhaus</surname><given-names>V</given-names></name> &amp; <name name-style="western"><surname>Ring</surname><given-names>D</given-names></name></person-group>. <article-title>The National Hospital Discharge Survey and Nationwide Inpatient Sample: the databases used affect results in THA research</article-title>. <source>Clinical Orthopaedics and Related Research</source><year>2014</year><volume>472</volume><fpage>3441</fpage>&#8211;<lpage>3449</lpage>. (<pub-id pub-id-type="doi">10.1007/s11999-014-3836-y</pub-id>)<pub-id pub-id-type="pmid">25091226</pub-id><pub-id pub-id-type="pmcid">PMC4182371</pub-id></mixed-citation></ref><ref id="bib28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>SN</given-names></name><name name-style="western"><surname>Wolford</surname><given-names>ML</given-names></name> &amp; <name name-style="western"><surname>Bercovitz</surname><given-names>A</given-names></name></person-group>. <article-title>Hospitalization for total knee replacement among inpatients aged 45 and over: United States, 2000&#8211;2010</article-title>. <source>NCHS Data Brief</source><year>2015</year><volume>210</volume><fpage>1</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">26375255</pub-id></mixed-citation></ref><ref id="bib29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>T</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Hao</surname><given-names>L</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Ren</surname><given-names>W</given-names></name> &amp; <name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name></person-group>. <article-title>Hepatitis C virus infection increases the risk of adverse outcomes following joint arthroplasty: A meta-analysis of observational studies</article-title>. <source>Orthopaedics and Traumatology, Surgery and Research</source><year>2022</year><volume>108</volume> 102947. (<pub-id pub-id-type="doi">10.1016/j.otsr.2021.102947</pub-id>)<pub-id pub-id-type="pmid">33930585</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>